Disease · MONDO_0008661
vitiligo
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. vitiligo. Diseases, record MONDO_0008661. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008661
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs65
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RUXOLITINIB | CHEMBL1789941 | Small molecule | Approval | EMA Human Drugs | 15 | 13 | 13 | Drugs and targets |
| MONOBENZONE | CHEMBL1388 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| TRIOXSALEN | CHEMBL1475 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| TACROLIMUS | CHEMBL3989887 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| AFAMELANOTIDE | CHEMBL441738 | Protein | Phase 3 | ClinicalTrials.gov | 5 | 4 | 4 | Drugs and targets |
| POVORCITINIB | CHEMBL5095079 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 3 | 3 | Drugs and targets |
| UPADACITINIB | CHEMBL3622821 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| RITLECITINIB | CHEMBL4085457 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 65
See all 65 drugsTargets92
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 14 | Glucocorticoid receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| JAK1 | Janus Kinase (JAK) | 5 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor | Approval | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK3 | Janus Kinase (JAK) | 5 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor | Approval | https://conductscience.org/library/genes/3718 | Drugs and targets |
| TYK2 | Janus Kinase (JAK) | 5 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator | Approval | https://conductscience.org/library/genes/7297 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 4 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor | Approval | https://conductscience.org/library/genes/3717 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 3 | FK506-binding protein 1A inhibitor | Phase 3 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 3 | HMG-CoA reductase inhibitor | Phase 2 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| VDR | Vitamin D3 receptor | 3 | Vitamin D receptor agonist | Phase 1 | https://conductscience.org/library/genes/7421 | Drugs and targets |
| COXFA4 | Mitochondrial complex I (NADH dehydrogenase) | 2 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/4697 | Drugs and targets |
| COXFA4L2 | Mitochondrial complex I (NADH dehydrogenase) | 2 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/56901 | Drugs and targets |
1 to 10 of 92
See all 92 targetsTrials84
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04530344 | Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo | Phase 3 | 458 | 2023-07-19 | Vitiligo | RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04057573 | Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) | Phase 3 | 344 | 2022-09-21 | Non-segmental Vitiligo | RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04052425 | Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) | Phase 3 | 330 | 2022-09-21 | Non-segmental Vitiligo | RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04927975 | Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo | Phase 2 | 185 | 2024-10-08 | Non-Segmental Vitiligo | UPADACITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04818346 | A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo | Phase 2 | 171 | 2023-07-05 | NonSegmental Vitiligo | POVORCITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03099304 | A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | Phase 2 | 157 | 2021-12-10 | Vitiligo | RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04338581 | Evaluation of AMG 714 for Vitiligo | Phase 2 | 60 | 2025-11-17 | Vitiligo | ORDESEKIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05247489 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo | Phase 2 | 55 | 2025-02-20 | Vitiligo | RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT05750823 | A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo | Phase 2 | 49 | 2026-03-20 | Nonsegmental Vitiligo With Genital Involvement | RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03468855 | A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo | Phase 2 | 34 | 2020-11-30 | Vitiligo | IFIDANCITINIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 84
See all 84 trialsComparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ruxolitinib Cream 1.5% BID vs Vehicle Cream BID: deaths from any cause | 0 of 326 | 0 of 115 | 441 | NCT04057573 | Trial comparisons |
| Ruxolitinib Cream 1.5% BID vs Vehicle Cream BID: serious adverse events | 6 of 326 | 0 of 115 | 441 | NCT04057573 | Trial comparisons |
| Ruxolitinib Cream 1.5% BID vs Vehicle Cream BID: deaths from any cause | 0 of 311 | 0 of 109 | 420 | NCT04052425 | Trial comparisons |
| Ruxolitinib Cream 1.5% BID vs Vehicle Cream BID: serious adverse events | 8 of 311 | 1 of 109 | 420 | NCT04052425 | Trial comparisons |
| Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID: Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period | 114 of 228 | 39 of 115 | 343 | NCT04057573 | Trial comparisons |
| Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID: Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period | 101 of 221 | 42 of 109 | 330 | NCT04052425 | Trial comparisons |
Treatment-Extension Period: Ruxolitinib Cream 1.5% BID vs Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID: Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Treatment-Extension Period | 82 of 199 | 38 of 98 | 297 | NCT04057573 | Trial comparisons |
Treatment-Extension Period: Ruxolitinib Cream 1.5% BID vs Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID: Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Treatment-Extension Period | 65 of 193 | 31 of 90 | 283 | NCT04052425 | Trial comparisons |
| AMG 714 vs Placebo: deaths from any cause | 0 of 41 | 0 of 18 | 59 | NCT04338581 | Trial comparisons |
| AMG 714 vs Placebo: serious adverse events | 0 of 41 | 0 of 18 | 59 | NCT04338581 | Trial comparisons |
1 to 10 of 16
See all 16 comparisons in its trialsPapers from its trials30
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008661
GET https://conductscience.org/api/diseases/v1/MONDO_0008661/drugs?page=2